- Johnson & Johnson (JNJ): 10.24%
- Eli Lilly and Co (LLY): 7.55%
- AbbVie Inc (ABBV): 6.08%
- Merck & Co Inc (MRK): 5.77%
- Bristol-Myers Squibb Co (BMY): 5.36%
- Vertex Pharmaceuticals Inc (VRTX): 5.13%
- Amgen Inc (AMGN): 4.38%
- Moderna Inc (MRNA): 4.33%
- Gilead Sciences Inc (GILD): 4.01%
- Regeneron Pharmaceuticals Inc (REGN): 3.96%
IEIH ETF — Holdings & Analysis
The iShares Evolved U.S. Innovative Healthcare ETF (IEIH) is a $0.04 billion fund seeking to capture the performance of U.S. listed innovative healthcare companies.
With an expense ratio of 0.18%, IEIH focuses on companies with economic characteristics historically correlated with the pharmaceutical and biotechnology sectors. IEIH's concentrated portfolio of just 8개 보유 종목 differentiates it from broader healthcare ETFs, offering a targeted approach to innovative healthcare exposure.
iShares Evolved U.S. Innovative Healthcare ETF (IEIH) ETF — Price, Holdings & Analysis
The iShares Evolved U.S. Innovative Healthcare ETF (IEIH) is a $0.04 billion fund seeking to capture the performance of U.S. listed innovative healthcare companies. With an expense ratio of 0.18%, IEIH focuses on companies with economic characteristics historically correlated with the pharmaceutical and biotechnology sectors. IEIH's concentrated portfolio of just 8개 보유 종목 differentiates it from broader healthcare ETFs, offering a targeted approach to innovative healthcare exposure.
ETF 개요
The fund invests, under normal circumstances, at least 80% of its net assets in U.S. listed common stock of large-, mid- and small-capitalization pharmaceutical and biotechnology companies. It will hold common stock of those companies that fall into the Innovative Healthcare Evolved Sector which have economic characteristics that have been historically correlated with companies traditionally defined as pharmaceutical and biotechnology companies. The fund is non-diversified.
IEIH aims to provide investors with exposure to U.S. listed companies in the innovative healthcare sector. The fund invests at least 80% of its net assets in the common stock of large-, mid- and small-capitalization pharmaceutical and biotechnology companies. IEIH focuses on companies that fall into the Innovative Healthcare Evolved Sector, selecting those with economic characteristics historically correlated with traditional pharmaceutical and biotechnology companies. This approach results in a concentrated portfolio; the fund currently holds only 8 stocks. The top holdings include Johnson & Johnson (10.24%), Eli Lilly and Co (7.55%), and AbbVie Inc (6.08%). With nearly all of its assets (99.9%) allocated to the Healthcare sector, IEIH offers a targeted investment vehicle for those seeking exposure to innovative healthcare companies. The fund is non-diversified, which means it invests a larger percentage of its assets in a smaller number of issuers than a diversified fund.
위험 지표
IEIH presents several risk considerations for investors. The fund's non-diversified status and small number of holdings (8) results in significant concentration risk; a downturn in any one of its top holdings could have a substantial negative impact on performance. Sector risk is also elevated, as nearly all (99.9%) of the fund's assets are allocated to the Healthcare sector, making it vulnerable to sector-specific headwinds. With a 3-year beta of 0.58, IEIH has historically exhibited lower volatility than the broader market. The fund's expense ratio of 0.18% will create a slight drag on returns over time, but is relatively low. Past performance does not guarantee future results.
운용보수율
0.18%
주요 보유 종목
펀드는 어떻게 배분되어 있나요?
- 헬스케어: 99.9%
- 기술: 0.1%
- 커뮤니케이션 서비스: 0.0%
- 미국: 49.6%
- 기타: 50.4%
배당수익률
1.34%
- State Street Technology Select Sector SPDR ETF (XLK) — 비용 비율 0.08%
- State Street Financial Select Sector SPDR ETF (XLF) — 비용 비율 0.08%
- State Street Energy Select Sector SPDR ETF (XLE) — 비용 비율 0.08%
- iShares Russell 2000 ETF (IWM) — 비용 비율 0.19%
- iShares MSCI EAFE ETF (EFA) — 비용 비율 0.32%
- Invesco QQQ Trust, Series 1 (QQQ) — 비용 비율 0.18%
- State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 비용 비율 0.16%
- AdvisorShares Vice ETF (VICE) — 비용 비율 1.71%
- iShares Russell 2000 ETF (IWM) (주식) — 비용 비율 0.19%
- iShares MSCI EAFE ETF (EFA) (주식) — 비용 비율 0.32%
- iShares Russell Mid-Cap ETF (IWR) (주식) — 비용 비율 0.18%
- iShares MSCI Emerging Markets Small-Cap ETF (EEMS) (주식) — 비용 비율 0.72%
- iShares MSCI USA Momentum Factor ETF (MTUM) (주식) — 비용 비율 0.15%
- iShares Blockchain and Tech ETF (IBLC) (주식) — 비용 비율 0.47%
위험 지표
- 베타: 0.58
질문 및 답변
What is IEIH and what does it track?
The iShares Evolved U.S. Innovative Healthcare ETF (IEIH) is an exchange-traded fund that seeks to track the performance of U.S. listed innovative healthcare companies. The fund invests primarily in common stock of pharmaceutical and biotechnology companies, focusing on those with economic characteristics historically correlated with the sector. IEIH aims to provide targeted exposure to the innovative segment of the healthcare industry. As of 2026-03-15, IEIH has an AUM of $0.04 billion and holds only 8 companies, making it a concentrated fund.
What is the expense ratio for IEIH?
The iShares Evolved U.S. Innovative Healthcare ETF (IEIH) has an expense ratio of 0.18%. This means that for every $10,000 invested in the fund, $18 is deducted annually to cover operating expenses. While expense ratios can vary widely among ETFs, IEIH's 0.18% is relatively low compared to the average expense ratio for equity ETFs, which hovers around 0.44%.
What are the top holdings in IEIH?
As of 2026-03-15, the top holdings in the iShares Evolved U.S. Innovative Healthcare ETF (IEIH) are concentrated in a few key companies. The top three holdings are Johnson & Johnson (JNJ) at 10.24%, Eli Lilly and Co (LLY) at 7.55%, and AbbVie Inc (ABBV) at 6.08%. These companies represent a significant portion of the fund's total assets, reflecting its focused investment strategy within the innovative healthcare sector. Other major holdings include Merck & Co Inc (MRK) and Bristol-Myers Squibb Co (BMY).
Is IEIH a good long-term investment?
Whether IEIH is a suitable long-term investment depends on an individual investor's risk tolerance, investment objectives, and time horizon. IEIH offers targeted exposure to the innovative healthcare sector, which may present growth opportunities. However, the fund's concentrated portfolio and sector-specific focus also introduce risks. With a 3-year beta of 0.58, IEIH has historically exhibited lower volatility than the broader market. The fund's expense ratio is 0.18%. Past performance does not guarantee future results. Investors should carefully consider these factors and conduct their own due diligence before investing.
How does IEIH compare to similar ETFs?
IEIH differentiates itself through its evolved sector approach and concentrated portfolio. Many healthcare ETFs offer broader diversification across the healthcare industry, while IEIH focuses specifically on innovative healthcare companies. With only 8개 보유 종목, IEIH is significantly more concentrated than most healthcare ETFs. The fund's expense ratio of 0.18% is competitive within the healthcare ETF landscape. However, its small AUM of $0.04 billion may be a concern for some investors, as smaller funds can have wider bid-ask spreads and may be more vulnerable to closure.
Does IEIH pay dividends?
Yes, the iShares Evolved U.S. Innovative Healthcare ETF (IEIH) does pay dividends. As of 2026-03-15, the fund has a dividend yield of 1.34%. This means that for every $100 invested in the fund, investors can expect to receive $1.34 in dividend payments annually. It's important to note that dividend yields can fluctuate over time and past dividend payments do not guarantee future results.